M
Monte Rosa Therapeutics, Inc. (GLUE)
NMS – Real Time Price. Currency in USD
19.11
-1.15 (-5.68%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
19.11
-1.15 (-5.68%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 9.54 | 6.05 | 10 | |
| Quick ratio | 9.54 | 5.63 | 10 | |
| Debt to Equity | 0.07 | 0.30 | 9.0 | |
| Debt to Assets | 0.05 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | 76M | 124M | 43M |
| Gross Profit | -9M | -6M | 68M | 115M | 35M |
| Operating Income | -112M | -143M | -81M | -54M | -148M |
| Net Income | -109M | -135M | -73M | -39M | -130M |
| EBITDA | -104M | -137M | -73M | -46M | -140M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -50.2 | -159.74 | 1.0 |
| Next quarter | -9.76 | -25.59 | 1.0 |
| Current year | -64.06 | -256.12 | 1.0 |
| Next year | 30.94 | -11.38 | 5.5 |
| Weighted average score | 2.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 51.38 | 3.54 | 16.67 | 10.38 | 7.5 |
| Y/Y | -95.03 | -194.91 | -178.94 | 16.66 | 3.0 |
| 3y average | 687.18 | 22.81 | 33.82 | 9.54 | 9.0 |
| 5y average | 811.91 | -16.87 | 30.94 | -37.03 | 5.5 |
| Weighted average score | 6.3 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $159.9M significantly exceed its total debt $39.1M, ensuring strong financial flexibility
Total current assets $677.5M exceed Total current liabilities $71.0M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$39.2M limits the company's ability to reinvest or pay down debt